tiprankstipranks
Blurbs

Sarepta Therapeutics (SRPT) Gets a Buy Rating from Needham

Needham analyst Gil Blum reiterated a Buy rating on Sarepta Therapeutics (SRPTResearch Report) today and set a price target of $150.00. The company’s shares closed last Tuesday at $89.16.

According to TipRanks.com, Blum is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -25.0% and a 16.4% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Rocket Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $122.73 average price target, implying a 36.4% upside from current levels. In a report issued on December 27, Oppenheimer also maintained a Buy rating on the stock with a $125.00 price target.

See the top stocks recommended by analysts >>

Sarepta Therapeutics’ market cap is currently $7.76B and has a P/E ratio of -14.55.

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SRPT in relation to earlier this year. Most recently, in December 2021, Kathleen Behrens, a Director at SRPT bought 5,000 shares for a total of $50,400.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Read More on SRPT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More